DSGN Design Therapeutics Inc: יתרת חוב לטווח ארוך של החברה

Design Therapeutics develops unique drugs to correct genetic defects, providing the company with market advantages in the therapy of rare pathologies. Design Therapeutics is expanding its scientific potential through alliances with laboratories, increasing its attractiveness for future acquisitions. Management is currently revising trial protocols to confirm molecular safety, while long-term debt stands at 0.00. This price chart on GURU.Markets visualizes the impact of these factors on capitalization.

Professional capital assesses the profile of Design Therapeutics (DSGN) through a liability structure with a maturity horizon of over one year. This indicator measures the volume of long-term loans, transforming quarterly data into a continuous stream of credit risk probabilities. By analyzing the trend of the business's long-term debt capital, the investor identifies a resource for scaling amidst sanction pressure on biotechnology. The stability of this metric confirms the financial resilience of Design Therapeutics (DSGN) during a slowdown in global research.